p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.

Humans Female Tumor Suppressor Protein p53 / genetics Ovarian Neoplasms / pathology Carcinoma, Ovarian Epithelial Carcinoma, Endometrioid / metabolism
TP53 clear cell endometrioid high-grade serous carcinoma ovarian cancer p53 prognosis

Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
05 2023
Historique:
revised: 06 01 2023
received: 23 11 2022
accepted: 11 01 2023
medline: 6 4 2023
pubmed: 23 3 2023
entrez: 22 3 2023
Statut: ppublish

Résumé

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.

Identifiants

DOI: 10.1002/cjp2.311 PMID: 36948887 PMC: PMC10073933
pubmed: 36948887
doi: 10.1002/cjp2.311
pmc: PMC10073933
doi:

Substances chimiques

Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-222

Subventions

Organisme : NCI NIH HHS
ID : R01 CA112523
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA069417
Pays : United States
Organisme : NIH HHS
ID : P30-CA15083
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA087538
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA095023
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00004/01
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA080668
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248288
Pays : United States
Organisme : Cancer Research UK
ID : 22905
Pays : United Kingdom
Organisme : NCRR NIH HHS
ID : M01 RR000056
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NIH HHS
ID : P50-CA136393
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168758
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NIH HHS
ID : R01-CA122443
Pays : United States
Organisme : NIH HHS
ID : R01-CA243483
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR000124
Pays : United States
Organisme : Cancer Research UK
ID : C490/A16561
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 15601
Pays : United Kingdom
Organisme : Breast Cancer Now
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA160669
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058598
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA136393
Pays : United States

Informations de copyright

© 2023 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

Références

Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Histopathology. 2019 Feb;74(3):452-462
pubmed: 30326146
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Gynecol Oncol. 2010 Jan;116(1):50-6
pubmed: 19822358
Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):859-68
pubmed: 20200435
PLoS One. 2013 Aug 13;8(8):e72609
pubmed: 23967324
Expert Rev Mol Med. 2008 Aug 01;10:e22
pubmed: 18671886
Clin Cancer Res. 2019 Jul 1;25(13):3962-3973
pubmed: 30967419
Ann Oncol. 2020 Sep;31(9):1240-1250
pubmed: 32473302
Clin Cancer Res. 2022 Nov 14;28(22):4947-4956
pubmed: 35816189
J Pathol. 2010 Oct;222(2):191-8
pubmed: 20629008
Int J Oncol. 2015 Feb;46(2):607-18
pubmed: 25385265
J Pathol Clin Res. 2021 Mar;7(2):144-153
pubmed: 33125840
J Pathol. 2020 Mar;250(3):312-322
pubmed: 31829447
Int J Gynecol Pathol. 2016 Jan;35(1):48-55
pubmed: 26166714
JAMA. 2012 Jan 25;307(4):382-90
pubmed: 22274685
Am J Surg Pathol. 2019 Dec;43(12):1591-1599
pubmed: 31335355
Am J Surg Pathol. 2021 Nov 1;45(11):1452-1463
pubmed: 34534137
Front Oncol. 2020 Jul 16;10:1103
pubmed: 32766142
Clin Cancer Res. 2020 Oct 15;26(20):5400-5410
pubmed: 32737030
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Am J Surg Pathol. 2019 Feb;43(2):161-167
pubmed: 30212391
Am J Surg Pathol. 2020 Jul;44(7):982-990
pubmed: 32384322
J Pathol Clin Res. 2016 Jul 13;2(4):247-258
pubmed: 27840695
Cancer. 1998 Mar 1;82(5):893-901
pubmed: 9486579
J Pathol. 2020 Mar;250(3):336-345
pubmed: 31829441
Int J Gynecol Pathol. 2021 Jan;40(1):32-40
pubmed: 33290354
J Pathol Clin Res. 2020 Oct;6(4):252-262
pubmed: 32391646
Int J Mol Sci. 2017 Feb 27;18(3):
pubmed: 28264438
Hum Pathol. 2008 Aug;39(8):1239-51
pubmed: 18602670
NPJ Precis Oncol. 2021 Jun 2;5(1):47
pubmed: 34079052
Br J Cancer. 2020 Feb;122(3):405-412
pubmed: 31780779
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Mod Pathol. 2017 Dec;30(12):1748-1759
pubmed: 28776572
J Pathol Clin Res. 2018 Oct;4(4):250-261
pubmed: 30062862
Int J Gynecol Pathol. 2016 Sep;35(5):430-41
pubmed: 26974996
J Pathol Clin Res. 2022 Jan;8(1):19-32
pubmed: 34596362
Am J Surg Pathol. 2021 Nov 1;45(11):1441-1451
pubmed: 33899789
J Pathol. 2022 Apr;256(4):388-401
pubmed: 34897700
Gynecol Oncol. 2019 Nov;155(2):318-323
pubmed: 31495455
Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):132-141
pubmed: 34697060
Int J Gynecol Cancer. 2019 Feb;29(2):346-352
pubmed: 30659026
PLoS Med. 2008 Dec 2;5(12):e232
pubmed: 19053170
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
Int J Gynecol Pathol. 2008 Apr;27(2):175-81
pubmed: 18317226
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Gynecol Oncol. 2022 Jun;165(3):577-584
pubmed: 35370008
Mod Pathol. 2021 Aug;34(8):1570-1587
pubmed: 33772212
Nat Commun. 2020 Oct 5;11(1):4995
pubmed: 33020491
Int J Gynecol Pathol. 2019 Jul;38(4):353-362
pubmed: 29901523

Auteurs

Martin Köbel (M)

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
ORCID: 0000-0002-6615-2037

Eun-Young Kang (EY)

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.

Ashley Weir (A)

School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
ORCID: 0000-0002-3072-2616

Peter F Rambau (PF)

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
Pathology Department, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania.

Cheng-Han Lee (CH)

Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.

Gregg S Nelson (GS)

Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Prafull Ghatage (P)

Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Nicola S Meagher (NS)

School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.

Marjorie J Riggan (MJ)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.

Jennifer Alsop (J)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Michael S Anglesio (MS)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, BC, Canada.
ORCID: 0000-0003-1639-5003

Matthias W Beckmann (MW)

Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Christiani Bisinotto (C)

Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

Michelle Boisen (M)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Jessica Boros (J)

Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.

Alison H Brand (AH)

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.

Angela Brooks-Wilson (A)

Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Michael E Carney (ME)

Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.

Penny Coulson (P)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Madeleine Courtney-Brooks (M)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Kara L Cushing-Haugen (KL)

Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Cezary Cybulski (C)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

Suha Deen (S)

Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, UK.

Mona A El-Bahrawy (MA)

Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK.

Esther Elishaev (E)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Ramona Erber (R)

Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
ORCID: 0000-0003-0315-1229

Sian Fereday (S)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Anna Fischer (A)

Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.

Simon A Gayther (SA)

Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Arantzazu Barquin-Garcia (A)

HM Sanchinarro Centro Integral Oncológico Clara Campal, University Hospital, Madrid, Spain.

Aleksandra Gentry-Maharaj (A)

MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.

C Blake Gilks (CB)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
ORCID: 0000-0001-7889-8250

Helena Gronwald (H)

Department of Propaedeutics, Physical Diagnostics and Dental Physiotherapy, Pomeranian Medical University, Szczecin, Poland.

Marcel Grube (M)

Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.

Paul R Harnett (PR)

Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.
Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.

Holly R Harris (HR)

Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Epidemiology, University of Washington, Seattle, WA, USA.

Andreas D Hartkopf (AD)

Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany.

Arndt Hartmann (A)

Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Alexander Hein (A)

Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Joy Hendley (J)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Brenda Y Hernandez (BY)

Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.

Yajue Huang (Y)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Anna Jakubowska (A)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.

Mercedes Jimenez-Linan (M)

Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK.

Michael E Jones (ME)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Catherine J Kennedy (CJ)

Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.

Tomasz Kluz (T)

Department of Gynecology and Obstetrics, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.

Jennifer M Koziak (JM)

Alberta Health Services-Cancer Care, Calgary, AB, Canada.

Jaime Lesnock (J)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Jenny Lester (J)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.

Jan Lubiński (J)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

Teri A Longacre (TA)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Maria Lycke (M)

Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.

Constantina Mateoiu (C)

Department of Pathology, University of Gothenburg, Gothenburg, Sweden.

Bryan M McCauley (BM)

Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.

Valerie McGuire (V)

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.

Britta Ney (B)

Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.

Alexander Olawaiye (A)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Sandra Orsulic (S)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.

Ana Osorio (A)

Genetics Service, Fundación Jiménez Díaz, Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Luis Paz-Ares (L)

H12O-CNIO Lung Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Teresa Ramón Y Cajal (T)

Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain.

Joseph H Rothstein (JH)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Matthias Ruebner (M)

Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Minouk J Schoemaker (MJ)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Mitul Shah (M)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Raghwa Sharma (R)

Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

Mark E Sherman (ME)

Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.

Yurii B Shvetsov (YB)

Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
ORCID: 0000-0001-5131-9618

Naveena Singh (N)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Helen Steed (H)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada.
Section of Gynecologic Oncology Surgery, North Zone, Alberta Health Services, Edmonton, AB, Canada.

Sarah J Storr (SJ)

Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham, UK.

Aline Talhouk (A)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, BC, Canada.

Nadia Traficante (N)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Chen Wang (C)

Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.

Alice S Whittemore (AS)

Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.

Martin Widschwendter (M)

EUTOPS Institute, University of Innsbruck, Innsbruck, Austria.

Lynne R Wilkens (LR)

Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.

Stacey J Winham (SJ)

Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.

Javier Benitez (J)

Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Andrew Berchuck (A)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.

David D Bowtell (DD)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Francisco J Candido Dos Reis (FJ)

Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

Ian Campbell (I)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
ORCID: 0000-0002-7773-4155

Linda S Cook (LS)

Epidemiology, School of Public Health, University of Colorado, Aurora, CO, USA.
Community Health Sciences, University of Calgary, Calgary, AB, Canada.

Anna DeFazio (A)

The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.

Jennifer A Doherty (JA)

Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.

Peter A Fasching (PA)

Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

Renée T Fortner (RT)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Research, Cancer Registry of Norway, Oslo, Norway.

María J García (MJ)

Computational Oncology Group, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Marc T Goodman (MT)

Cancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Ellen L Goode (EL)

Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.

Jacek Gronwald (J)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

David G Huntsman (DG)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
ORCID: 0000-0003-4934-3322

Beth Y Karlan (BY)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.

Linda E Kelemen (LE)

Division of Acute Disease Epidemiology, South Carolina Department of Health & Environmental Control, Columbia, SC, USA.

Stefan Kommoss (S)

Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.

Nhu D Le (ND)

Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.

Stewart G Martin (SG)

Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham, UK.

Usha Menon (U)

MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.

Francesmary Modugno (F)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA.

Paul Dp Pharoah (PD)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA.
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Joellen M Schildkraut (JM)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Weiva Sieh (W)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Annette Staebler (A)

Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.

Karin Sundfeldt (K)

Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.

Anthony J Swerdlow (AJ)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

Susan J Ramus (SJ)

School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.

James D Brenton (JD)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › p53 and ovarian carcinoma survival: an Ovarian...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › p53 and ovarian carcinoma survival: an Ovarian...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › p53 and ovarian carcinoma survival: an Ovarian...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Carcinome épithélial de l'ovaire › p53 and ovarian carcinoma survival: an Ovarian...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Carcinome endométrioïde › p53 and ovarian carcinoma survival: an Ovarian...